Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Tesamorelin
EfficacyHigh
Studies8
Participants1,459
StatusAvailable

Tesamorelin

Growth Hormone-Releasing Hormone (1-44) amide

Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.

Clinical Safety Profile

Reported Side Effects

Injection site reactions (erythema, pruritus, pain, swelling)
Joint pain and muscle pain
Peripheral edema (swelling in arms or legs)
Increased blood glucose levels
Potential insulin resistance
Upper respiratory tract infections
Paresthesia (tingling sensations)
Hypoesthesia (reduced skin sensitivity)
Nausea and gastrointestinal discomfort
Hot flashes
Night sweats
Irritability or mood changes

Side Effect Management (Clinical Trial Data)

Injection Site Reactions
Common
26.4%
Joint Pain
Common
15.7%
Peripheral Edema
Occasional
12.3%
Increased Blood Glucose
Common
18.9%
Upper Respiratory Infections
Infrequent
8.4%
Nausea
Infrequent
7.1%

Side Effect Management Strategies

Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise

Clinical Safety Metrics

Variable
Overall Safety Rating
Variable
Discontinuation Rate
Research
Approved Status

CONTRAINDICATIONS

• Active malignancy or history of malignancy
• Disruption of the hypothalamic-pituitary axis
• Hypersensitivity to tesamorelin or mannitol
• Critical illness or acute medical conditions

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Tesamorelin (Egrifta) is an FDA-approved prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment requires proper patient selection, monitoring, and management of potential side effects. Patients must be evaluated for contraindications including active malignancy and diabetic complications. Regular monitoring of glucose levels, IGF-1, and treatment response is essential for safe and effective use.